reports
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 L...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out ...
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugur...
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the...
Catalyst Pharmaceuticals Inc: 1 director
A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CE CELANESE CORPORATION
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
OXM OXFORD INDUSTRIES INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
WMG WARNER MUSIC GROUP CORP.
SPT SPROUT SOCIAL
IMVT INC.
NOG IMMUNOVANT INC
AMR NORTHERN OIL AND GAS
PBBK ALPHA METALLURGICAL RESOURCES INC
NRDY PB BANKSHARES
LUCY INC.
SMRT NERDY INC.
INNOVATIVE EYEWEAR INC
SMARTRENT INC
Option Care Health to Participate in the J.P. Morgan Healthcare Confer...
Option Care Health to Participate in the J.P. Morgan Healthcare Conference BANNOCKBURN, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the 44th Annual J.P. Morgan Healthcare Conference, being held in San Francisco, on Tuesday, January 13, 2026, including a presentation at 10:30am PT. The webcast and related presentation materials will be available online at . About Option Care Health Option Care Health is the nation’s larges...
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of ...
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and 10.0 months with gedatolisib + fulvestrant (“gedatolisib doublet”) versus 1.9 months for fulvestrantFor patients enrolled in the U.S., Canada, Western Europe, and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
NRIM NORTHRIM BANCORP INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
ALTG ALTA EQUIPMENT GROUP INC.
AMR ALPHA METALLURGICAL RESOURCES INC
NEXT NEXT CAPITAL
NRDY NERDY INC.
IMMX IMMIX BIOPHARMA INC
QDEL QUIDEL CORP
SMRT SMARTRENT INC
MNR MACH NATURAL RESOURCES LP
GAM GENERAL DE ALQUILER DE MAQUINARIA
TENX TENAX THERAPEUTICS INC.
AFCG AFC GAMMA
INC.
- Jonathan Moreland
NWBI NORTHWEST BANCSHARES INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
DIN DINE BRANDS GLOBAL INC.
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
TZOO TRAVELZOO
NHF NEXPOINT CREDIT STRATEGIES FUN
DMAC DIAMEDICA THERAPEUTICS INC.
ZIP ZIPRECRUITER
NRDY INC.
LIN NERDY INC.
MXF LINDE PUBLIC LIMITED COMPANY
MDRR THE MEXICO FUND
GF INC.
CBIO MEDALIST DIVERSIFIED REIT INC.
SINT THE NEW GERMANY FUND
GMRE INC.
SEVN CRESCENT BIOPHARMA INC.
SINTX TECHNOLOGIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
- Jonathan Moreland
- Jonathan Moreland
PCTY PAYLOCITY HOLDING CORP.
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
ALG ALAMO GROUP INC.
TZOO TRAVELZOO
INSE INSPIRED ENTERTAINMENT
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VLA ARBOR METALS
ALIT ALIGHT
PBBK INC. / DELAWARE
MAIA PB BANKSHARES
MNR INC.
KTTA MAIA BIOTECHNOLOGY INC
MACH NATURAL RESOURCES LP
PASITHEA THERAPEUTICS CORP
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of t...
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will inclu...
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Confere...
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 7:30 a.m. ET on Wednesday, December 3, 2025. A live webcast of the event will be available using this weblin...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
- Jonathan Moreland
RPD RAPID7 INC.
LOB LIVE OAK BANCSHARES
JACK JACK IN THE BOX INC.
HFWA HERITAGE FINANCIAL CORPORATION
EGBN EAGLE BANCORP INC.
DIN DINE BRANDS GLOBAL INC.
CLX CLOROX COMPANY
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
INSE INSPIRED ENTERTAINMENT
MLP MAUI LAND & PINEAPPLE CO. INC.
USPH U.S. PHYSICAL THERAPY
AEYE INC.
UTZ AUDIOEYE INC
AUID UTZ BRANDS INC (A)
NEXT IPSIDY INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
CWGL EVOLV TECHNOLOGIES HLDGS INC
QDEL CRIMSON WINE GROUP
WEST LTD
PROP QUIDEL CORP
SPRU WESTROCK COFFEE COMPANY LLC
GF PRAIRIE OPERATING CO.
NOV SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
NATIONAL OILWELL VARCO
INC. 
Celcuity Inc: 1 director
A director at Celcuity Inc sold 15,000 shares at 100.001USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the ™, a ranking of the 500 fastest-growing tec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.